

Novartis NEN

Novartis NEN

Novartis NEN

Novartis

Novartis NEN

Novartis NEN

Novartis NEN

Novartis NEN

Novartis NEN

1 Novartis NEN

	Novartis	Novartis
Novartis ^{1,2}	<ul style="list-style-type: none"> Novartis 92% 51% Novartis 38% Novartis 43% 23% 	Novartis NIPHS
Novartis Zollinger-Ellison Novartis ^{1,2}	<ul style="list-style-type: none"> Novartis 26 98 Novartis 0 56 Novartis 71 93 Novartis 17 73 Novartis 8 75 	Novartis G

<ul style="list-style-type: none"> • 22% 90% • 14% 18% • 54% 90% 	
<ul style="list-style-type: none"> • 89% 100% • 67% 100% • 44% 100% • 14% 33% 	
<ul style="list-style-type: none"> • 58% 100% • 45% 96% • 3% 18% • 14% 41% 	

NIPHS: non-insulinoma pancreatogenous hypoglycemia syndrome, WDHA: watery diarrhea hypokalemia achlorhydria

1 Ito T, Jensen R. Expert Opin Pharmacother. 2021; 22: 685-693.

2 . 2014; 111: 2263-2271.

3 Khan MS, et al. World J Gastroenterol. 2020; 26: 4537-4556.

NEN
 US CEUS CT MRI
 CT MRI US EUS SRS
 SASI test PET/CT 2 US CT MRI FDG-PET/CT SRS

NEN

	<ul style="list-style-type: none"> • CT/MRI • US • EUS/EUS-FNA • SASI test
--	--

膵臓がん	<ul style="list-style-type: none"> • CT/MRI • US • 膵臓造影/EUS • SASI test • 膵臓EUS-FNA • SRS
膵臓神経内分泌腫瘍	<ul style="list-style-type: none"> • CT/MRI • US • 膵臓造影/EUS • SASI test • SRS • ⁶⁸Ga-DOTATOC PET/CT
MEN1/VHL	<ul style="list-style-type: none"> • CT/MRI • EUS/EUS-FNA • SASI test • SRS
膵臓NEN	<ul style="list-style-type: none"> • CT/MRI • US • EUS/EUS-FNA • SRS
膵臓NEN	<ul style="list-style-type: none"> • 膵臓造影 • 膵臓EUS-FNA
NEN	<ul style="list-style-type: none"> • CT/MRI • US • FDG-PET/CT • SRS

SASI: selective arterial secretagogue injection, US: ultrasonography, EUS: endoscopic ultrasonography, EUS-FNA: endoscopic ultrasound-guided fine needle aspiration, PET: positron emission tomography

膵臓神経内分泌腫瘍の診断と治療に関する膵臓がん 2. 膵臓神経内分泌腫瘍NENの診断と治療に関する膵臓がん 2, 膵臓神経内分泌腫瘍 (NETS), 膵臓, 膵臓, 2019.

膵臓

NENのNET G1/G2のNECのMiNENの診断と治療に関する膵臓がん 2. WHOの2019の膵臓神経内分泌腫瘍のKi-67の診断と治療に関する膵臓がん [NENの診断と治療に関する膵臓がん](#)

膵臓神経内分泌腫瘍

膵臓